A Phase Ib Dose Escalation Study of MK4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs Niraparib (Primary) ; Carboplatin; Doxorubicin liposomal; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck & Co
- 02 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 02 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.